Your browser is no longer supported. Please, upgrade your browser.
GTHX G1 Therapeutics, Inc. monthly Stock Chart
GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own9.10% Shs Outstand31.34M Perf Week16.17%
Market Cap1.50B Forward P/E- EPS next Y-3.09 Insider Trans- Shs Float24.66M Perf Month-5.89%
Income-68.50M PEG- EPS next Q-0.66 Inst Own75.00% Short Float5.78% Perf Quarter18.74%
Sales- P/S- EPS this Y-181.70% Inst Trans36.91% Short Ratio4.75 Perf Half Y143.07%
Book/sh6.24 P/B7.68 EPS next Y-12.00% ROA-49.40% Target Price57.40 Perf Year181.49%
Cash/sh6.20 P/C7.72 EPS next 5Y- ROE-53.80% 52W Range12.04 - 52.76 Perf YTD141.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.16% Beta-
Dividend %- Quick Ratio15.60 Sales past 5Y- Gross Margin- 52W Low306.81% ATR3.06
Employees44 Current Ratio15.60 Sales Q/Q- Oper. Margin- RSI (14)64.37 Volatility6.87% 7.55%
OptionableNo Debt/Eq0.00 EPS Q/Q-13.30% Profit Margin- Rel Volume1.36 Prev Close47.91
ShortableYes LT Debt/Eq0.00 EarningsMay 23 AMC Payout- Avg Volume300.23K Price48.98
Recom1.70 SMA2010.36% SMA5013.70% SMA20067.22% Volume83,861 Change2.23%
May-29-18Initiated H.C. Wainwright Buy $61
May-18-18Reiterated Needham Buy $42 → $60
Jun-08-18 07:00AM  G1 Therapeutics Announces Appointment of New Members to the Board of Directors GlobeNewswire
Jun-06-18 08:20AM  Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-04-18 05:34PM  Hatteras Venture Partners sells 20 percent of shares in G1 American City Business Journals -10.16%
Jun-02-18 09:00AM  G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-30-18 03:18PM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX) Business Wire -6.65%
07:00AM  Wired News - Protalix BioTherapeutics Presents Data About Fabry Disease Patients Screened in Phase-III BALANCE Study ACCESSWIRE
May-29-18 10:06PM  Glancy Prongay & Murray LLP Begins Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX) Business Wire
03:44PM  HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets Benzinga
May-16-18 05:07PM  G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-09-18 03:46PM  Edited Transcript of GTHX.O earnings conference call or presentation 3-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-03-18 04:01PM  G1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update GlobeNewswire
May-01-18 07:00AM  G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018 GlobeNewswire
Apr-26-18 07:00AM  G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018 GlobeNewswire
Apr-16-18 06:00AM  G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer GlobeNewswire
Apr-09-18 07:40AM  Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-29-18 08:48AM  These 3 Biotech Stocks Are Soaring, but Are They Buys Now? Motley Fool
Mar-16-18 08:10AM  New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-14-18 02:25PM  G1 CEO talks 2018 growth American City Business Journals
08:48AM  G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher Zacks
Mar-12-18 04:05PM  G1 Therapeutics Announces Closing of Offering of Common Stock GlobeNewswire
Mar-07-18 09:54PM  G1 Therapeutics Announces Pricing of Offering of Common Stock GlobeNewswire +14.35%
Mar-05-18 04:18PM  G1 Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
03:30PM  G1 sees stock bump on big data readout American City Business Journals
07:40AM  Wired News FDA Granted Fast Track Designation to FibroGens Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer ACCESSWIRE
06:00AM  G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer GlobeNewswire
Mar-01-18 07:00AM  G1 Therapeutics to Present at Investor Conferences in March 2018 GlobeNewswire +5.67%
Feb-26-18 06:19PM  Edited Transcript of GTHX.O earnings conference call or presentation 21-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-21-18 04:01PM  G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Feb-14-18 07:00AM  G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018 GlobeNewswire
Jan-02-18 07:00AM  G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-18-17 07:00AM  G1 Therapeutics Added to Nasdaq Biotechnology Index GlobeNewswire
Dec-06-17 04:54PM  G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-17 07:00AM  G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer GlobeNewswire
Nov-11-17 12:01AM  [$$] Triggering a Debt Bomb Barrons.com
Nov-08-17 07:30AM  G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
07:00AM  G1 Therapeutics Makes Key Executive Appointments GlobeNewswire
Nov-07-17 08:00AM  G1 Therapeutics to Present at Stifel 2017 Healthcare Conference GlobeNewswire
Nov-06-17 07:00AM  G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response GlobeNewswire
Jun-09-17 10:42AM  Retail Investors: Your IPOs Are Here Benzinga
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.